AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02339532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
Study NCT02339532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
Study NCT02339532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: CARBOPLATIN AUC 6 IV q3w
Study NCT04553471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Treatment will take approximately 2 weeks.
Study NCT04553471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
Study NCT02230020 — intervention group
Intervention type: DEVICE
Intervention: Nasal High Flow
Study NCT01661244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568 repeat dose
Description: Safety and tolerability of escalating repeat doses in normal human volunteers.
Study NCT01661244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568 matching placebo repeat dose
Description: Safety and tolerability of escalating repeat doses in normal human volunteers.
Study NCT04606394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Description: Administration of Trelegy in all patients
Study NCT04606394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ventolin 90Mcg/Actuation Inhalation Aerosol
Description: 2 hours after the administration of Trelegy, administer Ventolin in all patients
Study NCT03574272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Transfer Monitoring System
Description: The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
Study NCT04271514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: Antagonist of the CCR4 chemokine receptor
Study NCT02494245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STARFISH
Description: The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
Study NCT00996554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double layer-suture
Description: Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
Study NCT05322889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan tablets
Description: 12 weeks treatment
Study NCT02119260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Clear, colourless solution of aqueous citrate buffer with 4% captisol
Study NCT00996554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-layer suture
Description: Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
Study NCT02119260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suspension
Description: Visually matching aqueous suspension of hypromellose acetate succinate powder
Study NCT02119260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching white opaque placebo blend filled capsule
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F Metered Dose Inhaler (MDI) 25/5 mcg
Description: MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F MDI 50/5 mcg
Description: MF/F MDI 50/5 mcg, 2 inhalations BID
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F MDI 100/5 mcg
Description: MF/F MDI 100/5 mcg, 2 inhalations BID
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP hydrofluoroalkane (HFA) 80 mcg
Description: BDP HFA 80 mcg, 2 inhalations BID
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast tablets 5 mg (4 mg for children 5 years of age)
Description: Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: short-acting beta-2 agonist (SABA) MDI
Description: albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed
Study NCT01615874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication: Prednisone/Prednisolone
Description: Prednisone/Prednisolone for rescue medication, taken as directed
Study NCT03578003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy
Description: 60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
Study NCT01928420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: NIC5-15
Description: A natural product, found in many foods and plants with mild insulin sensitizing effects
Study NCT01928420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Alzheimer's Disease placebo comparator
Study NCT04079348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oasis ECM
Description: The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
Study NCT04079348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard wound care
Description: The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
Study NCT02978755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 escalating doses (phase1)
Study NCT02978755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102 escalating doses
Description: GM102 escalating doses combined with paclitaxel and carboplatin
Study NCT02978755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM102
Description: GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
Study NCT04837300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted Sprint Traininig
Description: The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
Study NCT00022412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: doxercalciferol
Description: Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
Study NCT00022412 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional surgery
Description: Procedure: Prostatectomy for prostate cancer
Study NCT02344043 — intervention group
Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Description: This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
Study NCT03880838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal testimonial
Description: Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
Study NCT01214603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: Administered intravenously
Study NCT02739984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection with an automated mini doser
Study NCT02739984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection with an automated mini doser
Study NCT00624767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (recombinant human insulin)
Description: Insulin Nasal Spray at doses up to 200 IU.
Study NCT00624767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: NovoLog at doses up to 30 IU
Study NCT02419638 — intervention group
Intervention type: DRUG
Intervention: Rebif (IFN β-1a subcutaneous three times per week)
Study NCT02419638 — intervention group
Intervention type: DRUG
Intervention: Tecifdera (dimethyl fumarate)
Study NCT02394132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Study NCT02394132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT01148290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension free vaginal tape
Description: Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
Study NCT01148290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bulking agent injection
Description: Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
Study NCT01557595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarized glasses designed to filter out blue light
Description: Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so.
Study NCT01616303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
Study NCT01616303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
Study NCT01616303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
Study NCT01616303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
Study NCT01616303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oregovomab
Description: oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
Study NCT04366700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with autograft and collagen membrane
Description: periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
Study NCT04366700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery with collagen membrane
Description: periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
Study NCT03136991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4831
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
Study NCT03880838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forks Over Knives Documentary
Description: Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
Study NCT03880838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment nudge
Description: At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
Study NCT03880838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention nudge
Description: As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
Study NCT00265980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Placebo
Description: Twice daily injections of saline in the same volume as will be used for leptin injections.
Study NCT00265980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
Study NCT05988021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.
Study NCT00780858 — intervention group
Intervention type: DRUG
Intervention: Ganirelix
Description: Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
Study NCT04381520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion plus antihypertensive drugs
Description: In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
Study NCT04381520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive drugs
Description: In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
Study NCT04271514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03684148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery practice
Description: In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
Study NCT01371773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repositioning method for left-sided double lumen tubes
Description: When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
Study NCT03501433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside chloride (Niagen)
Description: 250 mg capsules 2x/day for 7 days
Study NCT03501433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2x/day for 7 days
Study NCT03136991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
Study NCT03020472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2008-2009 FluMist LAIV (Intranasal)
Description: 2008-2009 FluMist vaccine delivered intranasally
Study NCT03316859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 MG
Description: Naloxegol 25 mg administered 1 hour pre-operatively
Study NCT03316859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill administered 1 hour pre-operatively
Study NCT02489890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells
Description: chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
Study NCT03404076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy CT
Description: Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
Study NCT03672500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%+Epinephrine 50mc
Description: Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
Study NCT03672500 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection of the perineum
Study NCT02044471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (using Sphygmomanometer)
Description: Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this.
Study NCT02117193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol intake
Description: The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
Study NCT02117193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol intake
Description: The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
Study NCT02117193 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep deprivation
Description: One night of sleep deprivation or one night of normal sleep.
Study NCT02117193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep deprivation
Description: One night of sleep deprivation or one night of normal sleep.
Study NCT01003886 — intervention group
Intervention type: DRUG
Intervention: Doxazosin mesylate GITS
Description: Doxazosin mesylate GITS 4mg to 8mg once daily
Study NCT00534625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: Single injection of zileuton 150 mg
Study NCT00534625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single injection of placebo
Study NCT00534625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: Single injection of zileuton 300 mg
Study NCT01976390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 0.75mg twice a day, Orally, starting on day of transplant